Recent advances in immunotherapy and vaccine development for peanut allergy

The development of vaccines plays a vital role in the effective control of several fatal diseases. However, effective prophylactic and therapeutic vaccines have yet to be developed for completely curing deadly diseases, such as cancer, malaria, HIV, and serious microbial infections. Thus, suitable vaccine candidates need to be designed to elicit appropriate immune responses. Nanotechnology has been found to play a unique role in the design of vaccines, providing them with enhanced specificity and potency. Nano-scaled materials, such as virus-like particles, liposomes, polymeric nanoparticles (NPs), and protein NPs, have received considerable attention over the past decade as potential carriers for the delivery of vaccine antigens and adjuvants, due to their beneficial advantages, like improved antigen stability, targeted delivery, and long-time release, for which antigens/adjuvants are either encapsulated within, or decorated on, the NP surface. Flexibility in the design of nanomedicine allows for the programming of immune responses, thereby addressing the many challenges encountered in vaccine development. Biomimetic NPs have emerged as innovative natural mimicking biosystems that can be used for a wide range of biomedical applications. In this review, we discuss the recent advances in biomimetic nanovaccines, and their use in anti-bacterial therapy, anti-HIV therapy, anti-malarial therapy, anti-melittin therapy, and anti-tumor immunity.

Download Full-text

Recent Advances in Immunology that Impact Vaccine Development

New Generation Vaccines ◽

10.1201/9781439834404-20 ◽

2004 ◽

pp. 319-361

Keyword(s):

Vaccine Development ◽

Recent Advances

Download Full-text

Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis

Seminars in Immunology ◽

10.1016/j.smim.2020.101431 ◽

2020 ◽

Vol 50 ◽

pp. 101431 ◽

Cited By ~ 1

Author(s):

Thomas J. Scriba ◽

Mihai G. Netea ◽

Ann M. Ginsberg

Keyword(s):

Mycobacterium Tuberculosis ◽

Immune Responses ◽

Vaccine Development ◽

Recent Advances

Download Full-text

Special Issue “Recent Advances in Morbillivirus Vaccine Development and Oncolytic Virotherapy”

Viruses ◽

10.3390/v12030341 ◽

2020 ◽

Vol 12 (3) ◽

pp. 341

Author(s):

Liang-Tzung Lin

Keyword(s):

Vaccine Development ◽

Rna Viruses ◽

Oncolytic Virotherapy ◽

Special Issue ◽

Negative Strand ◽

Recent Advances

Members of the Morbillivirus genus are enveloped, negative-strand RNA viruses that include a number of highly contagious pathogens important to humans and animals [...]

Download Full-text

Malaria Vaccine Development: Recent Advances alongside the Barriers

Journal of Bacteriology & Parasitology ◽

10.4172/2155-9597.1000300 ◽

2016 ◽

Vol 07 (06) ◽

Cited By ~ 1

Author(s):

Desalegn Nega ◽

Abebe Alemu ◽

Geremew Tasew

Keyword(s):

Malaria Vaccine ◽

Vaccine Development ◽

Recent Advances

Download Full-text

Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development

Molecules ◽

10.3390/molecules23071712 ◽

2018 ◽

Vol 23 (7) ◽

pp. 1712 ◽

Cited By ~ 39

Author(s):

Cinzia Colombo ◽

Olimpia Pitirollo ◽

Luigi Lay

Keyword(s):

Vaccine Development ◽

Fungal Infections ◽

Thick Layer ◽

Biological Properties ◽

Research Field ◽

Host Cells ◽

Recent Advances ◽

Initial Adhesion ◽

Immunogenic Proteins ◽

New Research

During the last decade there has been a growing interest in glycoimmunology, a relatively new research field dealing with the specific interactions of carbohydrates with the immune system. Pathogens’ cell surfaces are covered by a thick layer of oligo- and polysaccharides that are crucial virulence factors, as they mediate receptors binding on host cells for initial adhesion and organism invasion. Since in most cases these saccharide structures are uniquely exposed on the pathogen surface, they represent attractive targets for vaccine design. Polysaccharides isolated from cell walls of microorganisms and chemically conjugated to immunogenic proteins have been used as antigens for vaccine development for a range of infectious diseases. However, several challenges are associated with carbohydrate antigens purified from natural sources, such as their difficult characterization and heterogeneous composition. Consequently, glycoconjugates with chemically well-defined structures, that are able to confer highly reproducible biological properties and a better safety profile, are at the forefront of vaccine development. Following on from our previous review on the subject, in the present account we specifically focus on the most recent advances in the synthesis and preliminary immunological evaluation of next generation glycoconjugate vaccines designed to target bacterial and fungal infections that have been reported in the literature since 2011.

Download Full-text

Novel Concepts for HIV Vaccine Vector Design

mSphere ◽

10.1128/msphere.00415-17 ◽

2017 ◽

Vol 2 (6) ◽

Cited By ~ 8

Author(s):

Quazim A. Alayo ◽

Nicholas M. Provine ◽

Pablo Penaloza-MacMaster

Keyword(s):

Immune Responses ◽

Viral Vectors ◽

Vaccine Development ◽

Viral Vector ◽

Intracellular Pathogens ◽

Adaptive Immune Responses ◽

Adaptive Immune ◽

Recent Advances ◽

Robust Adaptive ◽

Selection Of

ABSTRACT The unprecedented challenges of developing effective vaccines against intracellular pathogens such as HIV, malaria, and tuberculosis have resulted in more rational approaches to vaccine development. Apart from the recent advances in the design and selection of improved epitopes and adjuvants, there are also ongoing efforts to optimize delivery platforms. The unprecedented challenges of developing effective vaccines against intracellular pathogens such as HIV, malaria, and tuberculosis have resulted in more rational approaches to vaccine development. Apart from the recent advances in the design and selection of improved epitopes and adjuvants, there are also ongoing efforts to optimize delivery platforms. Viral vectors are the best-characterized delivery tools because of their intrinsic adjuvant capability, unique cellular tropism, and ability to trigger robust adaptive immune responses. However, a known limitation of viral vectors is preexisting immunity, and ongoing efforts are aimed at developing novel vector platforms with lower seroprevalence. It is also becoming increasingly clear that different vectors, even those derived from phylogenetically similar viruses, can elicit substantially distinct immune responses, in terms of quantity, quality, and location, which can ultimately affect immune protection. This review provides a summary of the status of viral vector development for HIV vaccines, with a particular focus on novel viral vectors and the types of adaptive immune responses that they induce.

Download Full-text